BSX vs ELV

BSX presents a classic divergence between deteriorating technicals and strong fundamental growth. While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company exhibits robust revenue (15.9%) and earnings (18.5%) growth. The stock is currently trading near its growth-based intrinsic value ($55.75) and significantly below analyst targets ($96.66), with a highly attractive PEG ratio of 0.66 suggesting undervaluation relative to growth. Despite a severe 6-month price decline, the consistent track record of earnings beats and a low Forward P/E (15.26) support a bullish long-term outlook.

Elevance Health presents a complex value proposition characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock is objectively undervalued, trading below its Graham Number ($340.31) and significantly below its intrinsic value ($763.75), recent financial performance is concerning with a -44.8% Q/Q EPS decline. The combination of bearish technicals and insider selling offsets the attractive valuation and strong analyst buy ratings. Consequently, the stock appears to be in a transition phase where deep value meets fundamental weakness.